TAG:
pathology specimens
Oncology’s Potential Drives AP Lab Expansion
CEO SUMMARY: It is no coincidence that another public company is shifting its business focus and expanding its efforts to capture cancer-related anatomic pathology specimens. Demographic trends predict a steady increase in the number of new cancer cases yearly, while new technologies are …
Pathology “Condo Labs” Are New Business Ploy
CEO SUMMARY: We call ‘em pathology condominium laboratories. Other names are “pod labs” and “salon labs.” Whatever name is used, this new scheme by specialist physicians to capture pathology revenues may be the most significant threat to the anatomic pathology profession since t…
IMPATH Has a Buyer: Genzyme Pays $215 Mil
CEO SUMMARY: Two unexpected things happened in IMPATH’s Chapter 11 bankruptcy action. First, it attracted a buyer willing to pay the premium price of $215 million for its assets. Second, the buyer was not another laboratory company. Rather, it is a new entrant into the oncology diagnost…
New Competitors Line Up In Oncology Marketplace
CEO SUMMARY: Local pathology groups are advised to more closely track developments in the national market for oncology testing. Not only is big money targeting cancer testing, but a number of nimble, entrepreneurial start-up companies have begun to compete for specimens. Genzyme’s acqui…
Anatomic Path Trends Portend Deep Changes
CEO SUMMARY: Our biannual review of trends shaping the anatomic pathology profession reveals that a wide range of influences are active. The nation’s healthcare system is undergoing fundamental changes in how it views the quality of health services and how it will favor top-performing p…
Who’s Buying Labs? Activity Shifts Down
CEO SUMMARY: As the number of independent clinical laboratories dwindles, most remaining owners seem content to continue building their business—at least until a buyer makes them an offer “they can’t refuse.” Acquisitions of pathology group practices were also few in number during…
How “Lean” is Benefiting Early-Adopter Laboratories
CEO SUMMARY: First steps toward a radical change in clinical laboratory operations are under way in a handful of early-adopter laboratories. This movement is so new that little information about their successes can be published. But the early evidence is compelling. For those labs willing…
LabCorp Starts Tinkering With DIANON Systems
CEO SUMMARY: For almost two decades, DIANON Systems supported one of the most successful sales and marketing programs in the public laboratory sector. However, despite its pre-acquisition statements that it would retain DIANON’s operational integrity, LabCorp has already begun to implem…
Histology Lab Goes Mobile To Serve Customers On-Site
CEO SUMMARY: During the 1990s, pathologists at Palm Beach Pathology recognized that more and more procedures were being done in ambulatory surgery centers and physicians’ offices. To maintain access to these patients, Palm Beach Pathology developed a strategic marketing plan with a uniq…
Analysis of Lab Testing Market Reveals Competitive Shifts
CEO SUMMARY: Even as public lab and anatomic pathology companies enjoy sustained growth in specimen volumes and revenues, fundamental shifts in the basic marketplace have changed the competitive environment. Surprisingly, the most open market segment is anatomic pathology specimens referr…
CURRENT ISSUE
Volume XXXI, No. 5 – April 8, 2024
The fragmentation of consumer markets is reflected in clinical lab services, and The Dark Report examines this trend and how it will impact labs in the coming years. Also, The Dark Report notes that the FDA has issued a controversial memo to reclassify many high-risk IVD assays.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.